Alicia currently serves as Senior Vice President of Commercial for Revolution Medicines, leading a diverse team charged with bringing innovative targeted cancer therapies to market. Alicia is an active member of Revolution Medicines Cross Functional Executive Leadership Team, contributing to its portfolio strategy to maximize patient and business impact.

Alicia previously served as Vice President at Genentech, a member of the Roche group, holding a variety of leadership positions while working across the company’s oncology, hematology and COVID franchises in the US, Switzerland and Canada. Alicia’s work is known for significant contribution to lifecycle management, strategy development, marketing and launch of several commercialized drug therapies. Earlier this fall, Alicia received the 2024 Outstanding Alumna Award granted by the Davidson School of Chemical Engineering.